- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03067311
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy (I-CAT)
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy (I-CAT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Schizophrenia is one of the most devastating disorders that often results in a lack of functional recovery. Current treatments focused on remediating symptoms have shown only small successes in a return to functioning despite evidence of a dysregulated stress response. There is a fundamental gap in understanding the impact of allostatic overload in persons with schizophrenia that the investigators theorize is associated with deficits in functioning and with an increased vulnerability and relapse risk. The long-term goal is to test an intervention aimed at improving stress reactivity. The objective in this application is to develop and test the feasibility of a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping. The central hypothesis is that an intervention that improves stress reactivity as measured proximally by endocrine, immune, and autonomic indices will result in improved adaptive capacity, better role functioning, reduced risk of relapse, and decreased likelihood of disability for people in the early stages of schizophrenia.
The rationale for the proposed research is that stress reactivity may be a modifiable risk factor underlying functional deficits in schizophrenia. The intervention integrates two treatment approaches. The first is based on research showing that mindfulness meditation practice is associated with alterations in the neural processing of stressful events and targets adaptive responses to stress. The second focuses on providing a buffer against stress by using the self-generation of adaptive emotions with a positive psychology intervention, which is potentially associated with building protective social resources. These complimentary interventions provide a comprehensive synergistic approach for this population that could lead to more adaptive coping responses and create a buffer against stress
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Carrboro, North Carolina, United States, 27510
- UNC OASIS Carrboro
-
Carrboro, North Carolina, United States, 27510
- UNC STEP
-
Raleigh, North Carolina, United States, 27603
- UNC Oasis Wake
-
Raleigh, North Carolina, United States, 27610
- UNC Wake STEP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- meets Diagnostic and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia spectrum disorder according diagnostic checklist completed by individual's clinician
- age 15 to 35, both genders, and any ancestry
- currently receiving services from UNC OASIS, Schizophrenia Treatment and Evaluation Program (STEP), or a community clinic
- willing and able to provide informed consent
Exclusion Criteria:
- greater than 8 years of antipsychotic and/or psychological treatment for psychosis
- Intelligence Quotient (IQ) less than 80
- low stress level as reported by clinician or participant
- meets criteria for current substance dependence
- been hospitalized in the past month
- actively practicing meditation in the past year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: I-CAT
A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
|
I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g.
autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
|
ACTIVE_COMPARATOR: Treatment as Usual
Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
|
Treatment as usual defined by participant clinician at OASIS clinic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change Over Time on the mDES - Positive
Time Frame: Baseline, 4.5, 9, and 12 months
|
The modified self-report Differential Emotion Scale (mDES) assessed the frequency of experiencing discrete emotions from the previous week.
Items are endorsed on a five-point scale indicating frequency (0 = not at all, 4 = most of the time).
Items are summed to yield positive (mDES - Positive) and negative emotion (mDES - Negative) subscales (range for both 0-40).
Higher scores on the positive subscale indicate more positive emotions.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the mDES - Negative
Time Frame: Baseline, 4.5, 9, and 12 months
|
The modified self-report Differential Emotion Scale (mDES) assessed the frequency of experiencing discrete emotions from the previous week.
Items are endorsed on a five-point scale indicating frequency (0 = not at all, 4 = most of the time).
Items are summed to yield positive (mDES - Positive) and negative emotion (mDES - Negative) subscales (range for both 0-40).
Higher scores on the negative subscale indicate more negative emotions.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the QLS
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Quality of Life Scale (QLS) is a semi-structured 7-item interview with sub scales, including active acquaintances, social initiatives, occupational role functioning, degree of motivation, anhedonia, commonplace objects, and capacity for empathy.
The 7-items are rated on a 7-point scale with higher ratings reflecting less impaired functioning (total range 7-49).
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the FESFS
Time Frame: Baseline, 4.5, 9, and 12 months
|
The First Episode Social Functioning Scale (FESFS) is a 42-item self-report measure assessing social functioning in early SSD.
The FESFS includes a total score and eight subscales assessing: independent living skills, interacting with people in different contexts, social activities, intimacy, friendships, family relations, work, and school.
Domain scores are averaged with higher scores reflecting better perceived functioning (range 0-4).
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the PSS
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Perceived Stress Scale (PSS) is a ten-item self-report measure of the degree to which daily situations from the past week are perceived as stressful, unpredictable, uncontrollable, as well as how "overloaded" individuals feel (0 = never, 4 = very often).
Items are summed for a total score (range 0 - 40) with higher scores indicating more perceived stress.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the DSI
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Daily Stress Inventory (DSI) is a 58-item self-report measure assessing the frequency and intensity of stressful events within the past 24-hours.
If an event is endorsed, participants rate the amount of stress the event caused (0 = did not occur, 1 = occurred but was not stressful to 7 = occurred and caused me to panic).
The DSI yields an average impact rating (AIR; average impact of ratings given items endorsed [sum/frequency]; range 1-7) with higher scores indicating more daily stress.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on Salivary Cortisol Levels
Time Frame: Baseline, 9 months
|
Salivary cortisol levels were collected as a measure of psychological stress.
|
Baseline, 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change Over Time on the PANSS Total Score
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Positive and Negative Syndrome Scale (PANSS) assessed current symptoms.
PANSS items are rated on a seven-point scale with higher scores reflecting more severe symptoms (ICCs for study assessors >.90).
Items are summed for a total score (range 30 - 210).
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the FFMQ
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Five Facet Mindfulness Questionnaire (FFMQ) is a 39-item self-report measure assessing facets of being mindful in daily life (i.e., observing, describing, acting with awareness, non-reactivity to inner experience, and non-judging of inner experience).
Items are endorsed on a five-point scale (1 = never or rarely true to 5 = very often or always true) and averaged for a total score (range 1-5) with higher scores indicating greater mindfulness ability.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the SCS
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Self-Compassion Scale Short Form (SCS) is a 12-item self-report measure of self-compassion.
SCS items are endorsed on a five-point scale (1 = almost never to 5 = almost always) and are summed for a total score (range 12 - 60) with higher scores indicating higher levels of self-compassion.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Change Over Time on the PWB
Time Frame: Baseline, 4.5, 9, and 12 months
|
The Psychological Well-Being Scale (PWB) is a 54-item self-report measure with items endorsed on a seven-point scale (1 = strongly disagree to 6 = strongly agree).
Items are summed for a total score (range 54 - 324) with higher scores indicating better psychological well-being.
Assessed at 4.5 months, 9 months, 12 months.
|
Baseline, 4.5, 9, and 12 months
|
Respiratory Sinus Arrhythmia
Time Frame: 9 months
|
Index of heart rate variability assessed as the ratio of low-to-high frequencies in the respiratory-cardiac power spectrum.
Mean level respiratory sinus arrhythmia (RSA) derived from heart rate monitor worn while participants engaged in a 5-minute mindfulness exercise.
|
9 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David L Penn, PhD, The Unviersity of North Carolina at Chapel Hill
- Principal Investigator: Diana Perkins, MD, The Unviersity of North Carolina at Chapel Hill
- Principal Investigator: Piper S Meyer-Kalos, PhD, Minnesota Center for Chemical and Mental Health
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-1173
- 4R33MH100250-03 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophreniform Disorders
-
Centre for Addiction and Mental HealthNot yet recruitingSchizophrenia | Schizophreniform DisordersCanada
-
The Hong Kong Polytechnic UniversityNew Life Psychiatric Rehabilitation AssociationUnknown
-
UMC UtrechtCompletedSchizophrenia | Schizophreniform DisordersNetherlands
-
Bayside HealthCompletedSchizophrenia | Schizoaffective and Schizophreniform DisordersAustralia
-
Pakistan Institute of Living and LearningNot yet recruitingSchizophrenia | Schizoaffective Disorder | Psychosis | Schizophreniform Disorders
-
Centre for Addiction and Mental HealthUniversity of Maryland, Baltimore; National Institutes of Health (NIH); The Feinstein...CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisordersUnited States, Canada
-
SunovionCompletedSchizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderUnited States
-
Tangent DataStanley Medical Research InstituteCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisordersMoldova, Republic of
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesRecruitingSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified or Other Psychotic DisordersUnited States
Clinical Trials on I-CAT
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedImpacted TeethNorway
-
MedImmune LLCAstraZeneca; MedImmune LtdCompleted
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)TerminatedAsthma AtopicUnited States
-
National Institute of Allergy and Infectious Diseases...Circassia LimitedCompletedCat Allergy | Cat HypersensitivityCanada
-
Aier School of Ophthalmology, Central South UniversityUnknown
-
Swiss Tropical & Public Health InstituteCompletedSatisfaction | Station AtmosphereSwitzerland
-
Circassia LimitedCetero Research, San Antonio; Adiga Life Sciences, Inc.Completed
-
Massachusetts General HospitalCompletedHand SurgeryUnited States
-
Boston Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...WithdrawnDiabetes Mellitus, Type 2United States